Every round, fund close and exit we can source, with the article it was reported in and what it actually said.
A 2006 announcement on venture firm GBS Ventures' site reports Antipodean Pharmaceuticals has begun a Phase 2 trial of its MitoQ compound targeting mitochondrial dysfunction in Parkinson's disease; details are in an attachment.
Peptech's 2006 ASX announcement, reposted by GBS Ventures, reports its takeover of Promics; the page holds only a download link, with no price or further detail in the text.
Also GBS Ventures·GBS Ventures
Portland Orthopaedics wins US FDA approval for its Beacon Primary Knee, licensed from Signal Medical, and uses an AusIndustry grant to develop a revision knee product.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.
OPAL Therapeutics raised a US$6 million Series A, with GBS Venture Partners leading a syndicate including Alloy Ventures, Alta Partners and Uniseed, to develop HIV and hepatitis C immunotherapies from University of Melbourne technology.
CogState has signed agreements giving it up to A$1.28 million in non-dilutive funding from Pfizer over three years for paediatric cognitive tests, speech-analysis technology and dementia detection tools, with work undertaken in Australia.
Pharmaxis announced its Aridol Phase III asthma diagnostic trial has enrolled first patients across 28 US sites, with FDA marketing authorisation planned for 2006.
Medical device firm Sunshine Heart closed a roughly A$3.3 million placement to institutional investors, funding its clinical trial and C-Pulse driver work; the release also cites an earlier A$2.2 million Commercial Ready grant.
A 2005 GBS Ventures news post records Portland Orthopaedics' stock market debut at a 12% premium, with detail left to an attached document rather than given on the page itself.
Also GBS Ventures
A stub news page from GBS Ventures linking to an attached ASX release concerning Sunshine Heart, dated December 2005; the document's contents are not reproduced on the page.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures
A 2005 notice that Portland Orthopaedics, a Sydney hip and knee implant maker, planned a $5 million IPO, with a December ASX listing expected and Axis Financial Group brokering the offer.
Pharmaxis priced a two-tranche global capital raising: a US public offering plus an Australian institutional placement, with combined net proceeds around US$58.6 million (A$80 million) to fund drug development and manufacturing.
GBS Ventures' news page carries a brief entry linking to a downloadable Sunshine Heart ASX announcement, without describing what the announcement contains.
Medtech company Sunshine Heart has brought in Ruth Flynn as its first clinical affairs manager, to drive C-Pulse heart assist device trials across Australia and New Zealand from its Sydney head office.
A stub page on GBS Ventures' site offering a downloadable Sunshine Heart investor update from October 2005; the page itself carries no content, figures, or transactions.
Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.
Also GBS Ventures·GBS Ventures
University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.
Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com
ASX-listed medical device company Sunshine Heart appointed Melbourne heart transplant specialist Professor Don Esmore to its medical advisory board, which already includes academics from Penn State, Stanford and the Cleveland Clinic.
GBS Venture Partners closed its third life science fund at $145 million, exceeding its $120 million target, with backing from returning and new Australian institutional investors.
Surgeons in Auckland have placed the C-Pulse cardiac support device from Australian medtech Sunshine Heart into a patient for the first time, with further trial sites planned at Australian hospitals.
Sunshine Heart reported that surgeons at Auckland City Hospital implanted its C-Pulse heart device in a Class III heart failure patient, the procedure opening a trial of up to ten patients.
Melbourne drug-discovery firm Cortical has won an AusIndustry-administered federal R&D Start grant of $3.03 million, funding early clinical testing of its MIF-antagonist treatment candidate for inflammatory conditions.
Also GBS Ventures
Skalata Ventures' rebrand piece describes its first-cheque approach for AI founders and says its Fund III is now raising, with nothing committed and no figures stated.
Biography of Sir David Levene, New Zealand retailer who built and sold Levene and Co. to Skellerup, then backed startups through Lewis Holdings and supported many philanthropic causes.
Podcast profile of entrepreneur Stevan Premutico, covering his restaurant reservations startup Dimmi and its 2015 acquisition by TripAdvisor, plus his new venture me&u.
Mergr records growth capital firm Five V Capital's investment in BioPak, an Australian compostable packaging supplier, dated 1 December 2022, alongside the firm's other listed deals in DCA Group and Monson.
Also monson.com.au
BetterUp has reportedly ended its partnership with Prince Harry, while Netflix and Boeing withdraw sponsorship of the Invictus Games, casting doubt on the veterans' event and Harry's commercial ventures.
Profile of Farmbot, a Sydney agtech company monitoring livestock water systems, listing four venture rounds totalling $23 million, including a 2026 Series B backing its North American expansion.
Also Beef Central / Grain Central·AgFunderNews·SmartCompany·Startup Daily·Beef Central / Grain Central
Interview with Team Timbuktu founder Rhianna Knight on building an eco-friendly apparel brand, looking back at the crowd campaign that funded her first collection and teasing another to grow the range.
Podcast interview in which Team Timbuktu founder Rhianna Knight recounts launching a sustainable activewear label, validating it through crowdfunding, and her approach to ethical manufacturing and annual sustainability reporting.
Folklore Ventures founder story recalling its seed backing of Manuri Gunawardena's clinical trial matching startup HealthMatch, plus follow-ons in its Series A and December 2020 Series B alongside Square Peg.
A Perth company received a government spaceport establishment grant to assess sites and develop a business case for Western Australia's first spaceport facility.
Also Startup News (WA)·Startup Daily·Space Connect·The Urban Developer·SpaceNews
Transcelestial raised an undisclosed new round co-led by NTT Finance and Paspalis Capital, with several other investors participating, taking its total funding to USD 30.7 million as it expands laser communications in Japan and Australia.
Microsoft partner Engage Squared has received investment from Alceon to build its AI, data and agent capabilities across APAC; the undisclosed sum is the first deal from Alceon's newly launched private equity fund.
Nexsen's investor page invites applications for its IPO under an August 2025 prospectus lodged with the corporate regulator; the share sale has not completed, so no funding is recorded.
M&A database entry recording Oneflare's 2018 acquisition of home services booking platform Urban You, its third Australian internet software deal, following its 2015 purchase of Word Of Mouth Online.
CBS News broadcasts Margaret Brennan's conversation with Hugging Face's co-founder and chief executive about a breach of the company's systems by an autonomous agent arising from an OpenAI-trained model.
Lender Funding has hired Lauren Severino and Sam Hermon as business development managers for New South Wales, expanding its BDM team to five amid growth in bridging and construction lending across the state.
The university assessment platform has raised new backing co-led by SEEK Investments and Glitch Capital, which it will use to enter the American market.
Sales-coaching AI startup Hupo has announced a $10 million Series A, with DST Global Partners leading and four earlier backers returning for the round.
FaBA profiles My PlantCo, Mei Yong's venture turning Australian oats into foods like Oat Rice, describing a $5.6 million FaBA project with GRDC co-investment now advancing the Real Oats range toward commercialisation.
A public-interest profile arguing Starward Whisky markets Melbourne independence while omitting its 2023 acquisition by UK multinational Diageo, with profits flowing overseas.
RentBetter republishes a Balance the Grind interview in which founder and CEO Jeremy Goldschmidt describes his daily routine and mentions the proptech platform's recent funding round.
Nurture Her speaker page profiling Vinomofo's chief executive, covering the wine e-commerce firm's growth since 2011, overseas expansion, a US partnership and industry awards.
Sydney-based NFT gaming firm Immutable has secured $200 million in new backing spearheaded by Singapore's Temasek, valuing the company at $2.5 billion; Tencent, Mirae Asset, ParaFi Capital and Declaration Partners also joined.
Also cryptobriefing.com·checkcryptonews.com·TechCrunch Venture
Listed investor Chapmans announces a $1.5 million placement for SaaS firm Rision, taking a $300,000 direct stake with options to become largest shareholder; background recalls Rision's 2016 acquisition of RosterCloud.
Pay-equity software startup EvenBetter.ai has landed a half-million-dollar investment from Shearwater Capital ahead of next month's launch, as new Australian gender pay reporting rules take effect.
Decidr's co-CEO argues enterprise AI fails without rich context, framing the firm's Sugarwork and Rumi acquisitions as pairing workflow mapping with continuous capture of meeting knowledge to feed its orchestration platform.